G. Dranoff

Immunology · 2003–2017

A researcher in the Science corpus: 14 papers; trusts 11 researchers and is trusted by 17 researchers here, as inferred from the citation graph.

Subfields

Whom G. Dranoff trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. M. Smyth
  2. Arlene H. Sharpe
  3. G. Freeman
  4. E. Shevach
  5. G. Dunn
  6. A. Mellor

Who trusts G. Dranoff overall

  1. A. Muller
  2. J. Pollard
  3. Gerhard Christofori
  4. O. Finn
  5. J. DuHadaway
  6. M. Karin
  7. S. Perwez Hussain
  8. Haitian Lu
  9. C. Andersen
  10. J. Joyce

Papers from G. Dranoff's perspective

Ordered by how strongly the researchers G. Dranoff trusts endorse each paper. Same corpus, a different order for every researcher.

  1. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection (Nature Immunology)
  2. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. (Proceedings of the National Academy of Sciences of the United States of America)
  3. PD-1 and its ligands in tolerance and immunity. (Annual Review of Immunology)
  4. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. (Advances in Immunology)
  5. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. (Journal of Clinical Investigation)
  6. Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer (New England Journal of Medicine)
  7. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer (Proceedings of the National Academy of Sciences of the United States of America)
  8. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease (Nature)
  9. Immunosuppressive strategies that are mediated by tumor cells. (Annual Review of Immunology)
  10. Pembrolizumab for the treatment of non-small-cell lung cancer. (New England Journal of Medicine)

Their papers